

Opdivo® (nivolumab), Yervoy® (ipilimumab) – Updated indication, accelerated approval converted to traditional approval

- On April 8, 2025, the <u>FDA announced</u> the approval of <u>Bristol Myers Squibb's Opdivo (nivolumab)</u> plus <u>Yervoy (ipilimumab)</u>, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
- The FDA also converted the accelerated approval to traditional approval for single agent Opdivo for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- Opdivo and Yervoy are approved across multiple cancers. Refer to the individual drug labels for a complete listing of their indications.
- The approval of Opdivo plus Yervoy for the updated indication was based on CHECKMATE-8HW, a randomized, open-label study in immunotherapy-naïve patients with unresectable or metastatic CRC with known MSI-H or dMMR status. Patients were randomized to receive one of the following treatments: Opdivo every 3 weeks and Yervoy every 3 weeks for a maximum of 4 doses, then Opdivo every 4 weeks; Opdivo every 2 weeks for 6 doses, then Opdivo every 4 weeks; or investigator's choice chemotherapy. The major outcome measure was progression-free survival (PFS) in the following pre-specified settings: first-line setting: Opdivo plus Yervoy vs. chemotherapy; all lines: Opdivo plus Yervoy vs. Opdivo alone.
 - In the first line setting (n = 255), median PFS was not reached in the Opdivo plus Yervoy arm vs. 5.8 months in the chemotherapy arm (hazard ratio [HR] 0.21, 95% CI: 0.14, 0.32; p < 0.0001).
 - In all lines (n = 582), median PFS was not reached in the Opdivo plus Yervoy arm avs. 39.3 months in the Opdivo alone arm (HR 0.62, 95% CI: 0.48, 0.81; p = 0.0003).
- Refer to the Opdivo and Yervoy drug labels for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.